CD274 and non-small cell lung carcinoma: In the Impower010 trial, atezolizumab was evaluated after adjuvant platinum-based chemotherapy in patients with completely resected stage IB–IIIA NSCLC [16], showing a disease-free survival (DFS) improvement compared to the best supportive care in PD-L1 ≥ 1% tumors; notably, in PD-L1 ≥ 50% population, the reduction of risk in disease progression was 57%.